Nuvation Bio Inc. Files 10-K/A Amendment No. 1 for Fiscal Year Ended December 31, 2023

TL;DR

<b>Nuvation Bio Inc. has filed an amendment to its 2023 annual report, providing updated information for its Class A Common Stock and Warrants.</b>

AI Summary

Nuvation Bio Inc. (NUVB) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Nuvation Bio Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ending December 31, 2023. The filing was made on April 26, 2024. The company's Class A Common Stock and Warrants to Purchase Class A Common Stock are registered on the New York Stock Exchange under the symbols NUVB and NUVB.WS, respectively. Nuvation Bio Inc. was formerly known as Panacea Acquisition Corp, with a name change date of April 30, 2020. The company is incorporated in Delaware and has an IRS Employer Identification Number of 85-0862255.

Why It Matters

For investors and stakeholders tracking Nuvation Bio Inc., this filing contains several important signals. This amendment indicates that Nuvation Bio Inc. is providing updated financial and operational disclosures for the fiscal year 2023. The filing confirms the company's listing on the NYSE and its former identity, which may be relevant for historical context or investor tracking.

Risk Assessment

Risk Level: low — Nuvation Bio Inc. shows low risk based on this filing. The filing is an amendment to a previous report, suggesting it's for clarification or correction rather than new material events, thus posing low risk.

Analyst Insight

Investors should review the amendment to understand any changes or clarifications made to the company's 2023 annual report.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-04-26 — Filing Date (Date of filing)
• 001-39351 — SEC File Number (Commission File Number)
• 85-0862255 — IRS Number (IRS Employer Identification No.)

Key Players & Entities

• Nuvation Bio Inc. (company) — Registrant
• Panacea Acquisition Corp (company) — Former company name
• New York Stock Exchange (company) — Exchange where securities are registered
• NUVB (company) — Trading symbol for Class A Common Stock
• NUVB.WS (company) — Trading symbol for Warrants
• Delaware (company) — State of incorporation

FAQ

Industry Context

Nuvation Bio Inc. operates in the Pharmaceutical Preparations industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 13 or 15(d), and adheres to SEC regulations for annual reports and amendments.

What Investors Should Do

1. Review the full 10-K/A filing for detailed financial and operational information.
2. Monitor future filings for updates on Nuvation Bio Inc.'s performance and strategic initiatives.
3. Verify the company's stock and warrant trading status on the New York Stock Exchange.

Key Dates

• 2023-12-31: Fiscal Year End — Reporting period for the annual report
• 2024-04-26: Filing Date — Date the 10-K/A amendment was filed
• 2020-04-30: Name Change — Date Nuvation Bio Inc. changed from Panacea Acquisition Corp

Year-Over-Year Comparison

This is an amendment (10-K/A) to the previous annual report, indicating updates or corrections to the information originally filed for the fiscal year ended December 31, 2023.

Key Financial Figures

• $0.0001 — tered Class A Common Stock, Par Value $0.0001 Per Share Warrants to Purchase Class
• $14.3 billion — and was sold to Pfizer Inc. in 2016 for $14.3 billion. Between Medivation and founding Nuvati
• $168 million — ment and which was acquired in 2001 for $168 million by Cytyc Corporation. Dr. Hung received

Filing Documents

• nuvb-20231231.htm (10-K/A) — 864KB
• nuvb-ex10_17.htm (EX-10.17) — 56KB
• nuvb-ex10_18.htm (EX-10.18) — 49KB
• nuvb-ex10_19.htm (EX-10.19) — 42KB
• nuvb-ex10_20.htm (EX-10.20) — 203KB
• nuvb-ex10_21.htm (EX-10.21) — 104KB
• nuvb-ex10_22.htm (EX-10.22) — 212KB
• nuvb-ex10_27.htm (EX-10.27) — 40KB
• nuvb-ex31_3.htm (EX-31.3) — 14KB
• nuvb-ex31_4.htm (EX-31.4) — 14KB
• nuvb-ex32_2.htm (EX-32.2) — 12KB
• img113553229_0.jpg (GRAPHIC) — 6KB
• img114476750_0.jpg (GRAPHIC) — 6KB
• img135717733_0.jpg (GRAPHIC) — 2KB
• img135717733_1.jpg (GRAPHIC) — 1KB
• 0000950170-24-049137.txt (&nbsp;) — 3927KB
• nuvb-20231231.xsd (EX-101.SCH) — 1407KB
• nuvb-20231231_htm.xml (XML) — 12KB

Executive Compensation

Executive Compensation 11 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 17 Item 13. Certain Relationships and Related Transactions, and Director Independence 19 Item 14. Principal Accounting Fees and Services 21 PART IV Item 15. Exhibits, Financial Statement Schedules 21 Item 16. Form 10-K Summary 25

Signatures

Signatures 25 PART III

Directors, Executive Officer s and Corporate Governance

Item 10. Directors, Executive Officer s and Corporate Governance. Nuvation Bio's Board of Directors is divided into three classes. Each class consists, as nearly as possible, of one-third of the total number of directors, and each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors or, for certain vacancies, by the holders of Class B Stock or the directors elected or appointed by the holders of Class B Stock. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director's successor is duly elected and qualified. The Board of Directors presently has nine members, with three directors in each class. Biographical information about each of the current directors, including their ages as of the date of this Amendment, and a discussion of the qualifications, attributes and skills of each director is contained in the following section. Directors Continuing in Office until the 2024 Annual Meeting Min Cui, Ph.D., 55, has served as a member of our board of directors since his appointment in April 2024 in connection with the Company's acquisition of AnHeart Therapeutics, Ltd. Dr. Cui founded Decheng Capital LLC in 2011, where he has served as Managing Director since the firm's formation. From 2006 to 2011, Dr. Cui served as a principal at Bay City Capital, a venture capital firm. Prior to that, Dr. Cui served as Director of Strategic Investment for the Southern Research Institute, a not-for-profit organization concentrating on drug research and development. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals, a U.S. biotech company, and Hucon Biopharmaceuticals, a PRC pharmaceutical company. He served as the Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998 to 2002 and Chief Executive Off

View Full Filing

View this 10-K/A filing on SEC EDGAR